DEF 14A: Maquia Capital Seeks Extension to Complete Business Combination Amid Nasdaq Delisting Concerns

Maquia Capital Acquisition Corporation is seeking stockholder approval to extend the deadline for completing a business combination from August 7, 2024, to January 7, 2025, while facing potential delisting from Nasdaq.

Summary

• Maquia Capital Acquisition Corporation is holding a special meeting on August 7, 2024, to vote on a proposal to extend the deadline for completing a business combination from August 7, 2024, to January 7, 2025.
• The company has entered into a Business Combination Agreement with Velocium, Inc. on July 15, 2024, but believes there is insufficient time to complete the combination before the current deadline.
• If the extension is not approved, the company will liquidate and redeem public shares at an estimated per-share price of $11.74.
• The company is also seeking approval for an adjournment proposal to allow for further solicitation of proxies if needed.
• Nasdaq has determined to delist the company's securities, with trading suspended effective July 31, 2024, due to non-compliance with listing requirements.
• The Sponsor and insiders, owning approximately 79.6% of the outstanding shares, are expected to vote in favor of the extension.
• Public stockholders have the right to redeem their shares in connection with the extension vote.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the potential delisting from Nasdaq and the need for an extension, indicating challenges in completing the business combination within the original timeframe. However, the ongoing efforts to complete the business combination and the potential for stockholders to redeem shares provide some mitigation.

Positives

• The extension provides additional time to complete the proposed business combination with Velocium, Inc., potentially allowing stockholders to participate in a future investment.
• Stockholders retain the right to redeem their shares if they disapprove of the business combination, even if the extension is approved.
• The Sponsor has agreed to indemnify the company under certain circumstances to protect the trust account.

Negatives

• Nasdaq has decided to delist the company's securities due to non-compliance with listing requirements.
• If the extension is not approved, the company will liquidate, and warrants will expire worthless.
• Redemptions in connection with the extension could reduce the cash available to complete the business combination.
• There is no guarantee that the business combination will be completed even if the extension is approved.
• The company may be subject to a 1% excise tax on redemptions.

Risks

• There are no assurances that the Extension will enable the company to complete a Business Combination.
• The company's ability to consummate any Business Combination is dependent on a variety of factors, many of which are beyond its control.
• The company may be deemed a foreign person under the regulations relating to CFIUS and its failure to obtain any required approvals within the requisite time period may require it to liquidate.
• The Extension contemplated by the Charter Amendment Proposal contravenes Nasdaq rules and, as a result, may lead Nasdaq to suspend trading in the company's securities or lead its securities to be delisted from Nasdaq.
• The company may be deemed an investment company for purposes of the Investment Company Act, which would require it to institute burdensome compliance requirements and its activities would be severely restricted.

Future Outlook

The company intends to seek stockholder approval of the Business Combination as soon as practicable if the Extension Amendment Proposal is approved. If stockholders approve the Business Combination, the company expects to consummate the Business Combination as soon as possible following such stockholder approval.

Management Comments

• The Board believes that it is in the best interests of the stockholders to continue our existence until the Extended Date in order to allow us more time to complete the Business Combination.
• The Board has determined that it is in the best interests of our stockholders to extend the date by which the Company has to consummate a Business Combination to the Extended Date in order for our stockholders to have the opportunity to participate in our future investment.

Industry Context

This announcement is typical for SPACs nearing their expiration date, facing pressure to complete a business combination or liquidate. The potential delisting adds further urgency to the situation.

Comparison to Industry Standards

• The redemption rate and trust value are key metrics for comparing this SPAC to others in the industry.
• The $11.74 per share redemption value is within the typical range for SPACs, but the actual amount may vary based on claims and taxes.
• The decision to delist the company from Nasdaq is a significant negative event, as it reduces liquidity and investor confidence.
• Comparable companies facing similar situations include other SPACs nearing their expiration dates with pending business combinations and potential delisting risks.

Stakeholder Impact

• Stockholders have the opportunity to redeem their shares or participate in the potential business combination.
• Employees of Maquia Capital face uncertainty regarding their future employment.
• The target company, Velocium, is affected by the uncertainty surrounding the completion of the business combination.

Next Steps

• Stockholders will vote on the extension amendment and adjournment proposals on August 7, 2024.
• The company will file an amendment to the charter with the Secretary of State of the State of Delaware if the Extension Amendment Proposal is approved.
• The company will continue to work to consummate the Business Combination by the Extended Date.
• The Company may request that the Nasdaq Listing and Hearing Review Council (the Listing Council) review this decision.

Key Dates

Keywords

business combination, extension, redemption, delisting, proxy statement, SPAC, Maquia Capital, Velocium, Nasdaq